TCGA-CV-5444-01A-02R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 44eb0b78-9761-4131-b831-85e765a24e6b | — | — | 0.930 |
| 2 | TCGA-K4-A3WS-01A-11R-A22U-07 | — | — | 0.909 |
| 3 | 20040019.LumA | — | A | 0.904 |
| 4 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.901 |
| 5 | TCGA-QK-A8Z9-01B-11R-A39I-07 | — | — | 0.901 |
| 6 | SRR6013599 | — | cohortMD2 | 0.899 |
| 7 | SRR26320092 | — | — | 0.894 |
| 8 | SRR2932812 | — | — | 0.890 |
| 9 | TCGA-97-8547-01A-11R-2403-07 | — | cohortA1 | 0.890 |
| 10 | ERR2278882 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.550 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |